PVM
RNTX

Palogic Value Management’s Rein Therapeutics RNTX Stock Holding History

Palogic Value Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$187K Hold
180,000
– – 0.06% 188
2026
Q1 		$234K Buy
+180,000
New +$223K 0.1% 165

Other funds holding RNTX

VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Palogic Value Management's RNTX Position: Q2 2026 in Review

Palogic Value Management held its Rein Therapeutics (RNTX) position steady in Q2 2026 at 180,000 shares worth $187K. The position accounts for 0.06% of the portfolio, ranked #188.

Palogic Value Management first reported a position in RNTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $234K in Q1 2026. 60 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

  • Palogic Value Management held 180,000 shares of Rein Therapeutics worth $187K as of Q2 2026.
  • Palogic Value Management left its Rein Therapeutics share count unchanged in Q2 2026.
  • Rein Therapeutics made up 0.06% of Palogic Value Management's portfolio in Q2 2026, its #188 holding.
  • Palogic Value Management first reported a position in Rein Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Palogic Value Management's Rein Therapeutics position peaked at $234K in Q1 2026.
  • 60 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on Palogic Value Management's 13F filing for Q2 2026, filed 14 Aug 2026.